Phase I/II Detox Support.
Support your livers natural detoxification. Unknown without ingredient list. Detox is a marketing term.
Reviewed March 2026
- Category
- Compound
- Also filed under
- Liver detox pathwaysToxin clearanceGlutathione
What Phase I/II Detox Support is, and what it does.
- Does it work
- Suits people who drink socially, live in heavy city air, or eat few fresh vegetables and want the conjugation cofactor pools topped up. Check which cofactors the label carries.
- How much to take
- 500 to 1,000mg a day is the maintenance band for a blend like this. Which cofactors appear on the label matters as much, since each conjugation route runs on its own pool.
- Time to feel it
- There is no onset to feel, because these are cofactors for liver enzymes. What changes is how quickly compounds get conjugated and exported, and that is measured in a lab.
- The first dose
- Day one starts topping up the cofactor pools. There's no sensation attached. What changes is how fast compounds get conjugated and exported, and that is read in a lab.
- With regular use
- Over weeks, steady intake keeps the glucuronic acid, sulfate, glutathione and methyl pools topped up so conjugation can keep pace with phase one. A supply story, not a sensation.
- How well tolerated
- Detox cleanses can be harsh. Your body detoxes fine on its own.
- How it feels
- There's no sensation attached to it. These are enzyme cofactors, so the effect sits in how quickly conjugation runs, which shows up in lab measures rather than in your day.
- The overlooked benefit
- Riboflavin and niacin sit inside phase one itself, as the flavin cofactor and the electron source for the reductase, so a blend without them is missing the front of the pathway.
500 to 1,000mg a day is where Phase I/II Detox Support works.
Source: Typical multi-ingredient supplement formulations
The proof, claim by claim.
These words describe the research, not the molecule's worth. Research strength is how much work stands behind one claim, and it is never a product score.
- Cofactor supply for phase two conjugationNarrative review
- Glutathione statusRandomised trial
- Nrf2-driven enzyme induction from glucosinolatesRandomised trial
- Urinary excretion of conjugated compoundsRandomised trial
- Everyday liver support from hepatobiliary botanicalsNarrative review
Questions people ask about Phase I/II Detox Support.
- When should I take it?
- Timing matters less than consistency. Pick a time that works for you and take it daily.
- Can I take it with other supplements?
- Usually fine. The main thing to watch is not doubling up on the same ingredient from different products. If you're on prescription meds, check with your pharmacist first.
- Any side effects to watch for?
- Most people tolerate it well at recommended doses. GI upset is the most common complaint with any supplement. Start with a lower dose and work up. If something feels off, stop and reassess.
- Who benefits most from this?
- People who've already covered the basics (diet, sleep, exercise) and want to fine-tune. It's not essential, but could be worthwhile for the right person.
Why these belong in the same formula. Each row says what the basis is, from settled biochemistry through to a trial that measured the pair.
Cysteine availability sets the rate of glutathione synthesis and NAC is the stable delivery form. Every downstream conjugation reaction that spends glutathione depends on that supply.
Glycine is one of the three residues in glutathione and is also the amino acid conjugated onto benzoate and related acids in phase II. Supplying it alongside cysteine covers both the tripeptide and the conjugation step.
Glutathione peroxidase carries selenocysteine at its active site, so selenium status limits how fast peroxides are cleared using glutathione. Without it, extra glutathione has less catalytic outlet.
Glutathione reductase is an FAD enzyme that returns oxidised glutathione to its reduced form using NADPH. Riboflavin status therefore governs how well the glutathione pool recycles rather than depletes.
Dihydrolipoic acid regenerates oxidised glutathione and vitamin C, feeding electrons back into the same network. It also raises cysteine uptake into cells, adding to glutathione synthesis.
Ascorbate regenerates the tocopheroxyl radical back to vitamin E and is itself regenerated by glutathione. The three form the recycling chain that keeps antioxidant capacity from being spent in one pass.
The molybdenum cofactor drives sulfite oxidase, the enzyme that converts sulfite from cysteine breakdown into sulfate. Sulfate is then the currency for sulfation, one of the main phase II conjugation routes.
Cystathionine beta-synthase and cystathionine gamma-lyase both require pyridoxal-5-phosphate to convert homocysteine into cysteine. B6 status therefore controls the endogenous supply of glutathione's rate-limiting amino acid.
5-MTHF donates the methyl group that regenerates methionine from homocysteine, keeping SAMe available for methylation reactions. Methylation is one of the phase II conjugation routes alongside sulfation and glucuronidation.
Methionine synthase needs cobalamin to transfer the methyl group from folate to homocysteine. Folate and B12 fail together, so methylation capacity depends on both being present.
Betaine homocysteine methyltransferase uses TMG rather than folate to remethylate homocysteine, giving a parallel path to methionine. It supports methylation capacity when the folate route is under load.
SAMe donates methyl groups for phase II methylation and its downstream metabolism feeds cysteine into glutathione synthesis through transsulfuration. It sits at the junction of both routes.
Taurine conjugates bile acids, which is how many fat-soluble metabolites leave the body through bile. Adequate taurine keeps that excretion route moving.
Glucaro-1,4-lactone from calcium D-glucarate inhibits gut beta-glucuronidase, the bacterial enzyme that cleaves glucuronide conjugates and frees their cargo for reabsorption. It preserves the work already done by phase II glucuronidation.
Sulforaphane modifies KEAP1 cysteines, releasing Nrf2 to raise transcription of glutathione S-transferases, NQO1 and glutamate cysteine ligase. That increases the enzymatic capacity the precursors then feed.
Broccoli sprout extract delivers glucoraphanin, which myrosinase or gut bacteria convert to sulforaphane. It is the food-form route to the same phase II enzyme induction.
Silybin stabilises hepatocyte membranes and raises intracellular glutathione content, alongside precursor and cofactor supply. It is the long-standing botanical anchor of liver support formulas.
DIM favours the 2-hydroxy route of oestrogen metabolism through CYP1A1 over the 16-alpha route, and those 2-hydroxy metabolites then need methylation and glucuronidation to leave. It pairs with methyl donors and glucarate for that reason.
Soluble fibre traps bile acids and their conjugated cargo in the gut so they leave rather than being reabsorbed at the ileum. Without a binding step, conjugates cleaved by gut bacteria simply recirculate.
Activated charcoal adsorbs by surface area with little selectivity, so it takes up vitamins, minerals and the botanical actives in the same dose. Anything given with it loses part of its delivered amount.
The chlorella cell wall binds lipophilic compounds in the gut and carries them out with the stool, working alongside fibre as a luminal binder. It acts before absorption rather than at the enzyme level.
Phase II conjugation through glutathione S-transferase consumes reduced glutathione, attaching it to electrophilic intermediates generated by phase I oxidation. Without adequate substrate that step slows and reactive intermediates persist longer. Oral glutathione is largely hydrolysed to its constituent amino acids, so the delivered form matters when reading any claim about it.
Glutathione is a tripeptide of glutamate, cysteine and glycine, and cysteine availability sets the synthesis rate under most conditions. Supplying it supports the pool that conjugation draws on. Free cysteine oxidises readily, which is why N-acetylcysteine is the usual delivery choice.
Glutamine is deamidated to glutamate, which is the first residue joined to cysteine by glutamate-cysteine ligase in glutathione synthesis. It is rarely limiting in a well-fed adult, but it is part of the same three-amino-acid supply question as cysteine and glycine. This is settled pathway biochemistry rather than a trial finding.
Methylation by catechol-O-methyltransferase and the other methyltransferases uses SAM, which is formed from methionine and ATP. Methionine also feeds the transsulfuration route that generates cysteine for glutathione. Both arms of the phase II picture therefore trace back to the same amino acid.
Every phase I oxidation by a cytochrome P450 enzyme requires electrons delivered by NADPH through P450 reductase. NADPH is built on the nicotinamide nucleotide that niacin supplies. Glutathione reductase draws on the same NADPH pool to regenerate reduced glutathione, so the cofactor sits on both sides of the pathway.
Methionine adenosyltransferase needs magnesium-bound ATP to make SAM, and glutathione synthesis by glutamate-cysteine ligase is likewise ATP dependent. Sulfation also runs on PAPS, another ATP-derived cofactor. Magnesium status therefore sits underneath several conjugation steps at once.
Metallothioneins are cysteine-rich proteins that bind divalent metal ions, and their expression is driven by the zinc-sensing MTF-1 transcription factor. Zinc also sits structurally in numerous enzymes across the same handling pathways. This is settled biochemistry and needs no trial to state.
Phase II sulfotransferases transfer sulfate from PAPS, which is assembled from ATP and inorganic sulfate, and sulfate supply can become limiting at high conjugation demand. MSM is an organosulfur compound used as one dietary sulfur source. How efficiently MSM sulfur enters the sulfate pool is less well quantified than the pathway itself.
EGCG activates the Nrf2-ARE pathway, raising expression of glutathione S-transferase and NAD(P)H quinone oxidoreductase in cell and animal models. It is also a heavy substrate for the same glucuronidation and sulfation capacity, so at high doses it competes with whatever else is being conjugated. The pathway effects are well described in laboratory models; the size in people at supplement doses is less settled.
Curcumin raises Nrf2-driven phase II enzyme expression in laboratory models while itself being almost entirely glucuronidated and sulfated at first pass. The two facts pull in different directions: it turns the pathway up and simultaneously loads it. Blends that pair it with piperine raise its systemic exposure by inhibiting that same conjugation, which is a point worth reading carefully.
Quercetin is both an Nrf2 activator and an inhibitor of SULT1A1 and of CYP3A4 activity in laboratory systems. In a blend intended to support normal conjugation, adding a strong inhibitor of one arm is a real interaction to account for. It is also the reason quercetin can raise systemic exposure to other compounds taken with it.
Grape seed proanthocyanidins raise antioxidant-response element transcription in cell models, which is the rationale for their presence in these formulas. They also draw on the same glucuronidation capacity as everything else in the blend. Read the effect as mechanistic support rather than a measured clinical result.
Artichoke leaf is used for its choleretic action, increasing bile flow, which is one of the routes conjugated metabolites leave the body. Formulas built around conjugation therefore often include a bile-supporting botanical alongside the cofactors. The pairing is convention with a physiological rationale, not a trialled combination.
Dandelion root has a long record as a bitter used to support bile production, and biliary excretion is the exit route for many glucuronide conjugates. It appears alongside the phase II cofactors for that reason. The basis is traditional use plus the excretion pathway, not a combination trial.
Schisandrin and related lignans alter CYP3A activity in laboratory systems, which cuts both ways: it can change how other compounds are cleared. Schisandra is a long-standing component of liver support formulas in traditional practice. Anyone taking prescribed medication should raise a CYP-active botanical with their clinician.
Conjugates excreted in bile can be cleaved by bacterial beta-glucuronidase in the colon, freeing the parent compound for reabsorption through enterohepatic recirculation. Fermentable fibres shift the microbial community and the activity of that enzyme, and calcium D-glucarate is used in these formulas for the same reason. The direction of the shift depends on which organisms are favoured, so it is a modulating relationship rather than a simple additive one.
Short-chain fatty acids from fibre fermentation feed the colonic epithelium and support the tight-junction proteins that govern what crosses it. That barrier is upstream of the whole conjugation question, since it sets how much reaches the liver in the first place. The relationship is physiological, not a trial of the combination.
Phase I oxidation generates reactive intermediates in both lipid and aqueous compartments, and the two antioxidant systems cover different ones. Tocopherol terminates lipid peroxidation chains and is regenerated with help from ascorbate and glutathione. The compartment split is why formulas carry both a lipid-soluble and a water-soluble antioxidant.
Nothing specific on file for Phase I/II Detox Support. Match the label to the daily amount above, and tell your doctor what you take.
Not medical advice. Show the label to your pharmacist.What Phase I/II Detox Support actually does.
The body handles foreign compounds in three steps: change them, tag them, then push them out.
The first step can make a compound more reactive, not less, so the second step matters just as much.
There are six main tagging routes, and each one uses a different molecule the body has to supply.
Each tagging route has a limited supply of its tag, and several compounds can compete for the same one.
Where Phase I/II Detox Support comes from.
This is not one substance but a blend. The vitamins and amino acids are usually grown in fermentation tanks or made chemically, the plant parts are extracted with alcohol and water and measured for strength, and everything is then mixed to the recipe on the label.
The same molecule is reached more than one way. Which route a given product used is a manufacturing choice, and the finished compound is the same either way.
This is a formulation category rather than a single molecule, so the inputs span fermentation broths for amino acids, mineral ores and salts, cruciferous seed and sprouts, and cultivated botanicals.
Amino acid components such as cysteine, glycine and taurine come from microbial fermentation or chemical synthesis; the B vitamins are made by fermentation or by defined synthetic routes.
Silymarin, artichoke, dandelion and schisandra fractions are extracted with ethanol and water from dried plant material; broccoli sprout material is water extracted with the myrosinase activity either preserved or deliberately removed.
Each component is purified separately, by crystallisation for the amino acids and salts and by resin adsorption for the polyphenol and glucosinolate fractions.
Botanicals are standardised on a marker compound, silymarin percentage or glucoraphanin content, while nutrients are assayed against a reference standard.
The isolated components are dry blended to the label ratio and encapsulated or tableted, so the composition of any given product is a formulation decision rather than a property of a raw material.
Getting Phase I/II Detox Support from food.
The whole-food sources on file. A supplement closes the gap, it does not replace dinner.
A gram-for-gram figure (how much of each you would eat to match a dose) will appear here once it is sourced and reviewed. This page will not print a number it cannot cite.
The forms it comes in.
The essence, in one line each.
- A guided dietary and supplement programme was reported to raise phase II enzyme activity markers and shift antioxidant balance measures in healthy adults; the endpoints are biomarkers, not clinical outcomes.Open-label trial. Panda et al., 2023 (Nutrients). PMID 37432335 ↗
- A plant-based supplement was associated with changes in metabolic detoxification measures and self-reported quality of life scores in the participants studied.Open-label trial. El-Khodor et al., 2023 (Integrative Medicine). PMID 38144165 ↗
- Genetic variation in conjugation-enzyme genes was examined as a predictor of hepatic biomarker responses to a supplement; the relationships reported are associations between genotype and marker, not demonstrated causes.Cohort study. Schauer et al., 2025 (International Journal of Molecular Sciences). PMID 41155501 ↗
- A review describing Chlorella and Spirulina as multi-pathway biological response modifiers, including their reported binding and antioxidant-pathway activity.Narrative review. Rzeski et al., 2026 (Molecules). PMID 42197149 ↗
- A single case describing genomic and functional assessment used to guide a nutrition plan in a postmenopausal adult; a case report grounds no general effect.Case report. Noland et al., 2026 (Frontiers in Nutrition). PMID 41669077 ↗
These are the studies our verdict leans on, chosen from the 5 we read for Phase I/II Detox Support. The full linked list is below.
FDA Disclaimer: These statements have not been evaluated by the Food and Drug Administration. This information is for educational purposes only and is not intended to diagnose, treat, cure, or prevent any disease. Consult your healthcare provider before starting any supplement regimen.